Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2025 Jun 26;17(6):104832. doi: 10.4330/wjc.v17.i6.104832

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.

This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

PMC Copyright notice

The Nrf2 inhibitor ML385 (1 μmol/L) inhibited restoration of the Nrf2/HO-1 signaling pathway in an angiotensin II-treated H9C2 cells after Hydrogen treatment. A: Cell viability in each group; B: Representative western blotting of Nrf2, TFR1, SLC7A11, HO-1, FTH1, and GPX4 proteins; C: Relative levels of Nrf2, TFR1, SLC7A11, HO-1, FTH1, and GPX4 proteins. Data are expressed as the mean ± SD; n ≥ 3. ^aP < 0.05 and ^cP < 0.01: Ang II group vs control group; ^bP < 0.05 and ^dP < 0.01: Ang II+H₂ group vs Ang II group; ^eP < 0.05 and ^fP < 0.01: Ang II+H₂+ML385 group vs Ang II+H₂ group. MCT: Monocrotaline; H₂: Hydrogen; Ang II: An angiotensin II.